Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 53.27 +0.39 (+0.74%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,381,542 Open 53.77 Bid (Size) 51.90 (2) Ask (Size) 56.00 (1) Prev. Close 52.88 Today's Range 53.10 - 53.77 52wk Range 45.00 - 58.97 Shares Outstanding 1,250,690,553 Dividend Yield 3.57% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes November 01, 2024 Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support. Via Benzinga Exposures Product Safety Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? October 31, 2024 Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance. Via Benzinga Performance YTD +6.54% +6.54% 1 Month -3.97% -3.97% 3 Month +3.54% +3.54% 6 Month +7.99% +7.99% 1 Year +17.75% +17.75% More News Read More Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split October 28, 2024 Via The Motley Fool Why Sanofi Stock Flew Higher on Friday October 25, 2024 Via The Motley Fool Sanofi (SNY) Q3 2024 Earnings Call Transcript October 25, 2024 Via The Motley Fool Topics Earnings Exposures Financial Sanofi's Earnings Outlook October 24, 2024 Via Benzinga NASDAQ:SNY is probably undervalued for the fundamentals it is displaying. October 03, 2024 Via Chartmill Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent October 25, 2024 Via Benzinga Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat October 25, 2024 Via Investor's Business Daily Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast October 25, 2024 Via Benzinga Markets Mixed Again; DECK, SKX Beat After The Bell October 25, 2024 Via Talk Markets Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business October 21, 2024 Via Benzinga This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip? October 21, 2024 Via The Motley Fool European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer October 18, 2024 Via Benzinga France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block October 18, 2024 Via Benzinga Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R October 15, 2024 Via Benzinga World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice October 11, 2024 Via Benzinga Denali Therapeutics Stock Is Sliding After The Bell: Here's Why October 10, 2024 Via Benzinga Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields October 07, 2024 Via Benzinga 2 Artificial Intelligence Stocks That Could Deliver Explosive Gains October 07, 2024 Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report October 04, 2024 Via Benzinga Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati October 04, 2024 Via Benzinga Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses October 04, 2024 Via Benzinga Exposures Product Safety US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next October 01, 2024 Via Benzinga Topics Economy Exposures Interest Rates Week In Review: Zenas Raises $259 Million In IPO September 28, 2024 Via Talk Markets Topics Initial Public Offering Exposures Securities Market Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
